Replies to post #213801 on Biotech Values

[linhdtu]

Heck, who can argue with that ?

I was one who piled into enta in 2013 even as the pps was falling prior to the P3 results and as luck would have it, sold out at a reasonable high level before the script number trend for abbvie/enta became clear.

i also would agree with you regarding rvnc, although i am dilly dallying about running up my stake because i think i still have time before yr end 2017 P3 results.

however, going back to enta now wrt to NASH, does the data/results to date for edp305 give you enough of a clear understanding of its MOA ?

one thing i have always like/respect about enta is lack of mgt selling unlike other biotechs . they indeed are taking the same risk as i do buying their shares. i can't really ask for more than that.

[biomaven0]

>>My strategy vis-à-vis pre-phase-3 buying is simple: Bet on phase-3 being successful in cases where the drug’s MoA is well-understood and efficacy has effectively been established in phase-2, thus limiting the phase-3 risk to the surfacing of a latent safety problem.

Exactly. FGEN's roxa falls into this category too.

Most of the time I try to bet earlier than Ph 111. And I can't ever see myself playing something like an Alzheimer Ph III.

Peter